Home Interviews Asgard’s CEO on the EUR 30 million Series A financing

Asgard’s CEO on the EUR 30 million Series A financing

Cristiana Pires, CEO Asgard Therapeutics

Asgard’s CEO on the EUR 30 million Series A financing

22 March, 2024

Asgard Therapeutics is a biotech based in Lund developing an immune “Trojan horse” to defeat cancer. The company recently announced a EUR 30 million Series A financing to advance its cell reprogramming platform for immuno-oncology. Asgard’s CEO and co-founder Cristiana Pires stopped by the BioStock Studio to tell us all about it.

Watch the interview here:

YouTube video

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev

RELATED ARTICLESMORE FROM AUTHOR